Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 5/20 | 0.53 |
| ▸ | MMP2 | P08253 | 5/20 | 0.53 |
| ▸ | MMP9 | P14780 | 5/20 | 0.53 |
| ▸ | EGFR | P00533 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15121428 | 0.85 | HDAC2 (0.66) | HTTALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL15121430 | 0.85 | HDAC2 (0.66) | HTTALDH1A1HDAC3HDAC4HDAC1 | |
| (E)-N-Methoxycinnamamide SCHEMBL13527482 | 0.84 | ALDH1A1 (0.65) | HTTALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL5672865 | 0.83 | HDAC3 (0.58) | HTTALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL27689876 | 0.83 | HDAC3 (0.58) | HTTALDH1A1HDAC3HDAC4HDAC1 | |
| Guanidine SCHEMBL27689909 | 0.82 | HTT (0.60) | HTTALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL5436480 | 0.81 | HTT (0.56) | HTTALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL27709614 | 0.81 | HTT (0.56) | HTTALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL7670344 | 0.79 | ALDH1A1 (0.73) | HTTALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL1949533 | 0.79 | HTT (0.70) | HTTALDH1A1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617709-B1 | Guanidine derivatives as antiviral agents | BIOTRON LTD (AU) | 2022-11-16 | — | — | EP | disclosed |
| US-11192863-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2021-12-07 | — | — | US | disclosed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | disclosed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | disclosed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | disclosed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | disclosed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192863-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | HTT 998/4885ALDH1A1 2843/4885HDAC3 262/4885 |
| US-10472332-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | HTT 998/4885ALDH1A1 2843/4885HDAC3 262/4885 |
| US-20070099968-A1 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | HTT 1300/4885ALDH1A1 3221/4885HDAC3 409/4885 |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | HTT 998/4885ALDH1A1 2843/4885HDAC3 262/4885 |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | HTT 1378/4885ALDH1A1 3132/4885HDAC3 293/4885 |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | HTT 1378/4885ALDH1A1 3132/4885HDAC3 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.